中国银河证券指出医药板块估值经历较长时间调整近期已呈现显著结构性修复趋势但公募基金重仓持仓水平仍低于历史均值2025年在

智通财经
04 Aug
中国银河证券指出医药板块估值经历较长时间调整近期已呈现显著结构性修复趋势但公募基金重仓持仓水平仍低于历史均值2025年在支持引导商保发展的政策背景下支付端有望边际改善创新药械有望获益。1)持续看好医药创新:下半年创新药BD预计仍将持续国内丙类目录及商保政策有望推动估值继续提升。2)医药投融资有望复苏:二级市场繁荣有望带来一级市场投融资回升CXO及上游景气度向好。3)医疗器械有望触底回升:招投标数据已开始回暖以旧换新积压需求逐步释放。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10